Handbook of systemic drug treatment in dermatology

Handbook of Systemic Drug Treatment in Dermatology

Volumn , Issue , 2002, Pages 1-252

  Wakelin, S H ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057498578     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (329)

1. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4(40): 25–49.
2. Chen Y, Xue S, Dai W et al. Elevation of serum triglyceride and cholesterol levels from isotretinoin therapy with concomitant oral contraceptives. Pharmacoepidemiology and Drug Safety 1995; 4: 91–96.
3. Rollman O, Vahlquist A. Interactions of retinoids with other systemically administrative drugs. Retinoids Today and Tomorrow 1992; 28: 4–7.
4. Larsen FG, Jacobsen P, Knudsen J et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623–627.
5. Zachariae H. Dangers of methotrexate/etretinate combination therapy. Lancet 1988; 1 (8582): 422.
6. Shah IA, Witting PH, Omar G et al. The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 1993; 129: 395–398.
7. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109–116.
8. Berth-Jones J, Shuttleworth D, Hutchinson PE. A study of etretinate alopecia. Br J Dermatol 1990; 122: 751–755.
9. Chroni E, Georgiou S, Monastrili A, Paschalis C, Tsambaos D. Effect of short-term oral acitretin therapy on peripheral nerve function: A prospective neurological and neurophysiological study. Acta Derm Venereol 2001; 81: 423–425.
10. Gronhoj Larson F, Steinker B, Jacobson P et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000; 143: 1164–1169.
11. Lebwohl M, Drake L, Menter A et al. Consensus Conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45: 544–553.
12. Orfanos CE, Zouboulis CC, Almond-Roesler B et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53(3): 358–388.
13. Eady EA, Jones CE, Tipper JL et al. Antibiotic resistant propionibacteria acnes – need for policies to modify antibiotic uses. BMJ 1989; 306: 555–556.
14. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology 1993; 187: 193–196.
15. O’Brien S, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. 1998: 9: 215–220.
16. Okada N, Sato S, Sasou T et al. Characterization of pigment granules in minocyclineinduced cutaneous pigmentation. Br J Dermatol 1993; 129: 403–407.
17. LeCleach, Bocquet H, Roujeau JC. Reactions and interactions of some commonly used systemic drugs in dermatology. Dermatologic Clinics 1998; 16: 421–429.
18. Chiu A, Chuenkongkaew W, Cornblath W et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998; 126: 116–121.
19. Gough A, Chapman S, Wagstaff et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169–172.
20. Schaffer JV, Davidson DM, McNiff JM, Bolognia JL. Perinuclear antineutrophil cytoplasmic antibody – positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001; 44: 198–206.
21. Sturkenboom MC, Meier CR, Jick H et al. Minocycline and lupus-like syndrome in acne patients. Arch Int Med 1999; 159: 493–497.
22. Shapiro LE, Uetrecht J, Shear NH. Minocycline, perinuclear antineutrophil cytoplasmic antibody and pigment: The biochemical basis. J Am Acad Dermatol 2001; 45: 787–789.
23. Schlienger RG et al. Minocycline-induced lupus. Dermatology 2000; 200: 223–231.
24. Roy AK, Lavrovsky Y, Song CS et al. Regulation of androgen action. Vitamins and Hormones 1999; 55: 309–352.
25. Helfman T, Falanga V. Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 1995; 33 (2 pt 1): 254–258.
26. Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: A double-blind placebo controlled trial. J Dermatol 2001; 28: 299-302.
27. Cicardi M, Castelli A, Zingale LS et al. Side-effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99(2): 194–196.
28. Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24: 236–243.
29. Sinclair R. Male pattern androgenetic alopecia. BMJ 1998; 317: 865–869.
30. Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol 1996; 35(11): 770–778.
31. Shapiro J, Price VH. Hair regrowth: therapeutic agents. Dermatologic Clinics 1988; 16: 341–356.
32. Price VH. Treatment of hair loss. N Engl J Med 1999; 341: 964–973.
33. Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatologic Clinics 1996; 14(4): 803–811.
34. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112: 124–125.
35. Rittmaster RS. Hirsutism. Lancet 1997; 348: 191–195.
36. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol 1988; 118: 687–691.
37. Kaufman KD, Olsen EA, Whiting D et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39: 578–598.
38. Sawaya ME, Shapiro J. Androgenetic alopecia: New approved and unapproved treatments. Dermatologic Clinics 2000; 18: 47–61.
39. Faergemann J, Zehender H, Denouel J et al. Levels of terbinafine in plasma, stratum corneum dermis-epidermis without stratum corneum, sebum hair and nails during and after 250 mg terbinafine orally once per day for 4 weeks. Acta Derm Venereol (Stockh) 1993; 73: 305–309.
40. Jones TC. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 1995; 132: 683–689.
41. Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol 2000; 42: 1–20.
42. Cribier BJ, Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 2001; 145: 446-52
43. Bell–Syer SEM, Hart R, Crawford F et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatol Treat 2001; 12: 69–74.
44. Hamm H, Schwinn A, Brautigam M et al. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatol 1999; 140: 480–482.
45. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–248.
46. Krafchik B, Pelletier J. An open study if tinea capitis in 50 children treated with a 2- week course of oral terbinafine. J Am Acad Dermatol 1999; 41: 60–63.
47. Fuller LC, Smith CH, Cerio R et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001; 144: 321–327.
48. Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Expert Opin Pharmacother 2000; 1: 287–304.
49. Gupta A, Lambert J, Revuz J, Shear N. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 2001; 11: 6–10.
50. Jahangir M, Hussain I, Hasan UI et al. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139: 672–674.
51. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–248.
52. Bar-Oz B, Moretti ME, Bishai R et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am J Obstet Gynecol 2000; 183: 617–620.
53. Gupta AK, Hofstader SLR, Adam P et al. Tinea capitis: an overview with emphasis on management. Ped Dermatol 1999; 16: 171-189.
54. Mohrenschlager M, Schnopp C, Fresq H et al. Optimizing the therapeutic approach in tinea capitis of childhood with itraconazole. Br J Dermatol 2000; 143: 1001–1005.
55. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamics and pharmacokinetics properties, and therapeutic potential in superficial and systemic mycosis. Drugs 1990; 39: 877–917.
56. Stern JJ, Hartman BJ, Sharkey P et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcus: experience with 22 patients. Am J Med 1988; 85: 477–480.
57. Faergermann J, Mork NJ, Haglund A et al. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol 1997; 136: 575–577.
58. Mercurio MG, Silverman RA, Elewski BE. Tinea capitis: fluconazole in Trichophyton tonsurans infection. Ped Dermatol 1998; 15: 229–232.
59. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909–910.
60. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–248.
61. Debruyne D, Coquerel A. Pharmacokinetics of antifungal drugs in onychomycoses. Clin Pharmacokinet 2001; 40: 441–472.
62. Chien RN, Yang LJ, Lin PY et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatol 1997; 25: 103–107.
63. Boxenbaum H. Cytochrome P-450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 1999; 2: 89–91.
64. Elewski BE. Tinea capitis: a current perspective. J Am Acad Dermatol 2000; 42: 1–20.
65. Honig PK, Wortham DC, Zamani K et al. Terfenadine–ketoconazole interaction. Pharmacokinetic and electrographic consequences. JAMA 1993; 269: 1513–1518.
66. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13–34.
67. Van Tyle JH. Ketoconazole: mechanism of action, spectrum of activity, pharmacodynamics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 1984; 4: 343–373.
68. Anderson DW. Griseofulvin: biology and clinical usefulness. Ann Allergy 1965; 23: 103-110.
69. Friedlander SF, Suarez S. Pediatric antifungal therapy. Dermatologic Clinics 1998; 16: 527–537.
70. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother 1997; 31: 406–410.
71. Hussain I, Muzaffar F, Rashid T et al. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Med Mycol 1999; 37: 97–99.
72. Knasmuller S, Parzefall W, Helma C et al. Toxic effects of griseofulvin: disease models, mechanisms and risk assessment. Crit Rev Toxicol 1997; 27: 495–537.
73. Bennett ML, Fleischer AB, Loveless JW et al. Oral griseofulvin remains the treatment of choice for tinea capitis in children. Pediatr Dermatol 2000; 17: 304–309.
74. Stockley I. Drug Interactions. 5th edition. Pharmaceutical Press, London. 1999.
75. Mann RD, Pearce GL, Dunn N et al. Sedation with ‘non-sedating’ antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000; 320: 1184–1186.
76. Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001; 2: 27–32.
77. McEvoy GK. (Ed) American Hospital Formulary Service Drug Information. American Society of Health-System Pharmacists, Bethesda, 1997, pp. 2856–2858.
78. Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp All 1999; 29 (Suppl 1): 31–37.
79. Simons FER, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994; 330: 1663–1670.
80. Lin RY, Curry A, Pesola GR et al. Improved outcome in patients with allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 2000; 36: 462–468.
81. Greene SL, Reed CE, Schroeter AL. Double blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985; 12: 669–675.
82. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31: 633–635.
83. Wallace DJ. The history of antimalarials. Lupus 1996; 5 (Suppl 5): S2–3.
84. Gladman DD. Workshop report: aspects of use of antimalarials in systemic lupus erythematosus. J Rheumatol 1998; 25: 983–985.
85. Drake LA, Sontheimer RD et al. American Academy of Dermatology Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996; 34: 830–836.
86. Fielder A, Graham E, Jones S et al. The Royal College of Ophthalmologists 1998 Recommendations for Good Practice in Rheumatology and Dermatology Clinics. Available from the Royal College of Ophthalmologists.
87. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 3–7.
88. Spalton DJ, Verdon Roe GM et al. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 1993; 2: 355–358.
89. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75(1A): 40–45.
90. Parke AL. Antimalarial drugs in pregnancy. Scand J Rheumatol 1998; 27 (Suppl 107): 125–127.
91. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus (Cochrane Review). Cochrane Database Sys Rev 2001; 1: CD002954.
92. Trehan M. The use of antimalarials in dermatology. J Derm Treatment 2000; 11: 185–194.
93. Weiss JS. Antimalarial medications in dermatology: a review. Dermatologic Clinics 1991; 9: 377–385.
94. Younger IR, Harris DWS, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol 1991; 25: 281–286.
95. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J Royal Soc Med 1995; 88: 155–160.
96. Guillaume J-C, Vaillant L, Bernard P et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49–53.
97. Lennard L, Van Loon JA, Weinshillboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149–154.
98. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114–146.
99. Tanis AA. Azathioprine in inflammatory bowel disease: a safe alternative? Mediators of Inflammation 1998; 7: 141–144.
100. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. Arthritis Rheum 1989; 32: 837–843.
101. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38: 1722–1732.
102. Dutz JP, Ho VC. Immunosuppressive agents in dermatology: an update. Dermatologic Clinics 1998; 16: 235–251.
103. Knowles SR, Gupta AK, Shear NH et al. Azathioprine hypersensitivity-like reactions – a case report and review of the literature. Clin Exp Dermatol 1995; 20: 353–356.
104. Kornam NJ. Bullous pemphigoid: the latest in diagnosis, prognosis and therapy. Arch Dermatol 1998; 134; 1137–1141.
105. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001; 26: 369–375.
106. Mihatsch MJ, Wolfe K. Consensus conference on cyclosporin A for psoriasis 1992. Br J Dermatol 1992; 126: 620–626.
107. Ho VC, Griffiths CEM, Berth-Jones J et al. Intermittent short courses of cyclosporine (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol 1999; 141: 283–291.
108. Roos TC, Merk HF. Important drug interactions in dermatology. Drugs 2000; 59: 181–192.
109. Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 2000; 69(4): 522–526.
110. Dutz JP, Ho VC. Immunosuppressive agents in dermatology: an update. Dermatologic Clinics 1998; 16: 235–251.
111. Raddadi AA, Baker DZ. Cyclosporin and pregnancy. Br J Dermatol 1999; 140(6): 1197–1198.
112. Burden AD. Management of psoriasis in childhood. Clin Exp Dermatol 1999; 24(5): 341–345.
113. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142(1): 52–58.
114. Grattan CEH, O’Donnell BF, Francis DM et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000; 143 365–372.
115. Harper JJ, Berth–Jones J, Camp RD et al. Cyclosporin for atopic dermatitis in children. Dermatol 2001; 203: 3–6.
116. Koo J, Lee J. Cyclosporin what clinicians need to know. Dermatologic Clinics 1995; 13: 4, 897–905.
117. Naeyaert JM, Lachapelle JM, Degreef H et al. Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus. Dermatology 1999; 198(2): 145–152.
118. Powles AV, Hardman CM, Porter WM et al. Renal function after 10 years’ treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443–449.
119. Sidbury R, Hanifin JM. Old, new and emerging therapies for atopic dermatitis. Dermatologic Clinics 2000; 18(1): 1–8.
120. Clofazimine. In American Hospital Formulary Service Drug Information. (Ed) McEvoy GK. American Society of Health System Pharmacists, Bethseda, 1999, p.745.
121. Clofazimine. In Therapeutic Drugs. 2nd edition. (Ed) Dollery CT. Churchill Livingstone, Edinburgh, 1999, C272–275.
122. Arbiser JL, Moschella SL. Clofazimine: a review of its medicinal uses and mechanisms of action. J Am Acad Dermatol 1995; 32: 241–247.
123. Sukpanichnant S, Hargrove NS, Kachintorn U et al. Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. Am J Surg Pathol 2000; 24: 129–135.
124. Sanchez MR. Miscellaneous treatments: Thalidomide, Potassium Iodide, Levamisole, Clofazimine, Colchicine and D-penicillamine. Clinics Dermatol 2000; 18: 131–145.
125. Cronstein BN, Mould Y, Reibman J, Balakhane E, Levin RJ, Weissman G. Colchicine alters the quantitative and qualitative display of selertins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994–1002
126. Aram H. Colchicine in dermatologic therapy. Int J Dermatol 1983; 10: 566–568
127. Ang P, Tay YK. Treatment of linear IgA bullous dermatosis of childhood with colchicine. Pediatr Dermatol 1999; 16: 50–52.
128. Bandokar DD, al Suwaid AR. Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood. Int J Dermatol 1997; 36: 213–216
129. McEvoy GK (Ed). American Hospital Formulary Service Drug Information. American Society of Health-System Pharmacists, Bethesda, 1997, pp. 2856–2858.
130. Parfitt K (Ed). Martindale: The Complete Drug Reference. 32nd edition. Pharmaceutical Press, London, 1999, pp. 393–394.
131. Sanchez MR. Miscellaneous treatments: Thalidomide, Potassium Iodide, Levamisole, Clofazimine, Colchicine and D-penicillamine. Clinics Dermatol 2000; 18: 131–145.
132. Sullivan TP, King LE, Boyd AS. Colchicine in dermatology. J Am Acad Dermatol 1998; 39: 993–999.
133. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasonecyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119: 73–77.
134. Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 1999; 135: 57–61.
135. Frasier LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Drugs 1991; 42: 781–795.
136. Silvis NG. Antimetabolites and cytotoxic drugs. Dermatologic clinics 2001; 19: 105–118.
137. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488–498.
138. Fairchild WV, Spence CR, Soloman HD et al. The incidence of bladder cancer after cyclophosphamide therapy. J Urol 1979; 122: 163–164.
139. Pasricha JS, Khaitan BK. Curative treatment for pemphigus. Arch Dermatol 1996; 132: 1518–1519.
140. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arth Rheum 1995; 38: 1722–1732.
141. Dutz JP, Ho VC. Immunosuppressive agents in dermatology: an update. Dermatologic Clinics 1998; 16: 235–251.
142. Finn GP, Sidau RNB, Shaw IC. Protecting the bladder from cyclophosphamide with mesna. N Eng J Med 1986; 314: 61.
143. McDonald CJ. Cytotoxic agents for use in dermatology. J Am Acad Dermatol 1985; 12: 753–775.
144. Werth VP. Pulse intravenous cyclophosphamide for treatment of autoimmune blistering disease. Arch Dermatol 1997; 133: 229–230.
145. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone. Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukocyte Biol 1997; 62: 827–836.
146. Modschielder K, Weller M, Worl P et al. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Derm Res 2000; 292: 32–36.
147. Coleman MD. Dapsone modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993; 129: 507–513.
148. Bluhm RE, Adedoyin A, McCarver DG et al. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Therapeutics 1999; 65: 598–605.
149. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicol 2001; 162: 53–60.
150. Coleman MD, Scott AK, Breckenridge AM et al. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990; 30: 761–767.
151. Sanders SW, Zone JJ, Foltz RL et al. Haemolytic anaemia induced by dapsone transmitted through breast milk. Ann Int Med 1982; 95: 465–466.
152. Dollery CT. Dapsone. In Therapeutic Drugs. 2nd edition. (Ed) Dollery CT. Churchill Livingstone, Edinburgh, 1999, p. D11.
153. Paniker U, Levine N. Dapsone and sulphapyridine. Dermatologic Clinics 2001; 19: 79–86.
154. Zhu YI, Stiller MJ. Dapsone and sulphones in dermatology: Overview and update. J Am Acad Dermatol 2001; 45: 420–434.
155. Schweckendiek W. Heilnd von psoriasis. Med Monatschr 1959; 13: 103–104.
156. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 1999; 141: 424-429.
157. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139: 390–395
158. Stoof TJ, Sampat S, Neiboer, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144: 114–120.
159. Vandermeeren M, Janssens S, Wouters H et al. Dimethylfumarate is an inhibitor or cytokine-induced nuclear translocation of NR-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001; 116: 124–130.
160. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977–981.
161. Nuteren Huying WM, van der Schroeff JG, Hermas J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized double-blind placebo-controlled study. J Am Acad Dermatol 1990: 22: 311–312.
162. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assessment 2000: 4; 76–80.
163. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 190–196.
164. Youssef PP, Haynes DR, Triantafillon S et al. Effects of pulse methylprednisone on inflammatory mediators in peripheral blood, synovial fluid and synovial membrane in rheumatoid arthritis. Arthritis Rhuem 1997: 40:1400.
165. Williams LC, Nesbitt LT. Update on systemic glucocorticosteroids in dermatology. Dermatologic Clinics 2001; 19: 63–77
166. Sabir S, Werth VP. Pulse Glucocorticoids Dermatologic Clinics 2000; 18: 437–446.
167. Corticosteroids. In British National Formulary, London, 2001. Vol 41: 335–341.
168. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol 2001; 137: 477–481.
169. Travios S. Steroid psychosis: A cause of confusion on the accute spinal cord injury unit. Arch Phys Med Rehab 1993; 74: 312–315.
170. Werth VP. Glucocorticoids in dermatology. Current Opinion in Dermatol 1994; 51: 195–199.
171. Committee on Safety of Medicines and Medicines Control Agency. Focus on corticosteroid. Current Problems in Pharmacovigilance 1998; 24: 5–10.
172. Fitz KA, Weston WL. Systemic glucocorticosteroid therapy of skin disease in children. Ped Dermatol 1984; 3: 236–245.
173. Lucky AW. Principles for the use of glucocorticosteroid in the growing child. Ped Dermatol 1984; 3: 226–235.
174. American College of Rheumatology Task force on osteoporosis guidelines: recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Rheum 1996; 39: 1791–1801.
175. Eastell R, Reid DM, Compston J et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Int Med 1998; 244: 271–292.
176. Gebhard KL, Maibach HI. Relationship between systemic corticosteroids and osteonecrosis. Am J Clin Dermatol 2001; 2: 377–388.
177. Yarbro JW. Mechanism of action of hydroxyurea. Sem Onc 1992; 19 (Suppl 9): 1–10.
178. Leavell UW, Yarbro JW. Hydroxyurea: a new treatment for psoriasis. Arch Derm 1970; 102: 144–148.
179. Smith CH. Use of Hydroxyurea in psoriasis. Clin Exp Dermatol 1999; 24: 2–6.
180. Layton AM, Sheehan-Dare RA, Goodfield MJD et al. Hydroxyurea in the management of therapy of resistant psoriasis. Br J Derm 1989; 121: 647–653.
181. Williams REA. Guidelines for the management of patients with psoriasis. BMJ 1991; 303: 829–835.
182. Kirby B, Harrison PV. Combination low dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis. Br J Derm 1999; 140: 186–187.
183. Donehower RC. An overview of the clinical experience with hydroxyurea. Sem Onc 1992; 19 (Suppl 9): 11–19.
184. Moschella SL, Greenwald MA. Psoriasis with hydroxyurea. An 18-month study of 60 patients Arch Derm 1973; 107: 363–368.
185. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Derm 1991; 25: 518–524.
186. Burns DA, Sarkany I, Gaylarde P. Effects of hydroxyurea therapy on normal skin: a case report. Clin Exp Derm 1980; 5: 447–449.
187. Kennnedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea. Arch Dermatol 1975; 111: 183–187.
188. Moschella SL. Chemotherapy of psoriasis: ten years of experience. Int J Derm 1976; 15: 373–378.
189. Siriex ME, Debure C, Baudot N et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135: 818–820.
190. Wolverton SE. Systemic drug therapy for psoriasis. Arch Derm 1991; 127: 565–568.
191. Kirkwood J, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma. J Clin Oncol 2001; 19: 2370–2380.
192. Mielke V, Staib G, Sterry W. Systemic treatment for cutaneous lymphomas. Recent Results Cancer Res 1995; 139: 403–408.
193. Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2αplus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578–3581.
194. Stadler R. Interferons in dermatology: present day standard. Dermatologic Clinics 1998; 16: 377–398.
195. Aversa SM, Cattelan AM, Salvagno L et al. Chemoimmunotherapy of advanced AIDS related Kaposi’s sarcoma. Tumori 1999; 85: 54–59.
196. Mozzanica N, Cattaneo A, Boneschi V et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res 1990; 282: 311–317.
197. Ikic D, Padovan I, Pipic N et al. Local interferon therapy for lip carcinoma. Eur Arch Otorhinolaryngol 1994; 251: 292–296.
198. Ezekowitz RA, Mulliken JB, Folkmann J. Interferon alpha-2a therapy for life threatening haemangiomas of infancy. N Engl J Med 1992; 326: 1456–1463.
199. Hanifin SM, Schneider LC, Leung DY et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189–197.
200. Berman B, Sequira M. Dermatologic uses of Interferons. Dermatologic Clinics 1995; 13: 699–711.
201. Cooper KD. Atopic Dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994; 102: 128–137.
202. Macey WH. Interferon: an overview for dermatology nurses. Dermatology Nursing 1996; 8: 155–159.
203. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol/Oncol Clinics of North America 1995; 9: 1089–1107.
204. Ruszczak Z, Schwartz RA. Interferons in dermatology: biology, pharmacology and clinical applications. Adv in Dermatology 1998; 13: 235–287.
205. Dwyer JM. The clinical use of intravenous gamma globulin. In Immunology and Inflammation. Basic Mechanisms and Clinical Consequences. (Eds) Sigal LH, Ron Y. McGraw-Hill, Inc., New York, St. Louis, San Francisco, 1994, pp. 655–674.
206. Dalakas MC. Controlled Studies with high dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 1998; 51 (Suppl 5): S37–45.
207. Jolles S. A reveiw of high dose intravenous immunoglobulin (hd IVIg) in the treatment of autoimmune blistering diseases. Clin Exp Dermatol 2001; 26: 127–131.
208. O’Donnell BF, Barr RM, Kobza Black A et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101–106.
209. Wehrli IVP, Bullani R, Schneider P et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–493.
210. Jolles S, Hughes J, Rustin M. Treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000; 142: 551–554.
211. NIH Consensus Conference: Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990; 264: 3189–3193.
212. Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J AM Acad Dermatol 2001; 45: 775–783.
213. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J AM Acad Dermatol 2001; 45: 679–690.
214. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80–86.
215. Lundblad JL, Londeree N, Mitra G. Characterization of various intravenous immunoglobulin preparations. J Infection 1987; 15 (Suppl 1): 3–12.
216. Rutter A, luger TA. High dose intravenous immunoglobulin: An approach to treat severe immune-mediated and autoimmune diseases of the skin. J AM Acad Dermatol 2001; 44: 1010–1024.
217. Vahlquist A, Rollman O, Holland DB et al. Isotretinoin treatment of severe acne affects the endogenous concentration of vitamin A in the sebaceous glands. J Invest Dermatol 1990; 94: 496–498.
218. Cunliffe WJ, van der Kerkhof PCM, Capito R et al. Roaccutane treatment guidelines: Results of an international survey. Dermatology 1997; 194: 351–357.
219. Jones DH, Cunliffe WJ. Remission rates in acne patients treated with various doses of 13-cis-retinoic acid. Br J Dermatol 1984; 111: 123–125.
220. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27(2): 52–57.
221. Lehucher-Ceyrac D, Weber Buissel JJ, Puissant A. Isotretinoin and acne in practice. A prospective analysis on 188 cases over 9 years. Dermatology 1993; 186: 123–128.
222. MacDonald Hull S, Cunliffe WJ. The safety of isotretinoin in patients with acne and systemic diseases. J Dermatol Treat 1989; 1: 35–37.
223. Gerber LH, Helfgott RK, Gross CG et al. Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol 1984; 10: 817–823.
224. Lyons F, Laker MF, Marsden JR et al. Effects of oral 13-cis-retinoic acid on serum lipids. Br J Dermatol 1982; 107: 591.
225. Amichai B, Grunwald MH. Isotretinoin in dermatology. J Dermatol Treat 2000; 11: 219–240.
226. Cunliffe WJ. (Ed) Side effects of acne therapy. In Acne. Martin Dunitz, London, 1989, pp. 288–324.
227. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin useage. Am J Ophthalmol 2001; 132: 299–305.
228. Irvine C, Kumar P, Parks P. Isotretinoin in the treatment of rosacea and rhinophyma. In Acne and related disorders. (Eds) Marks R, Plewig G. Martin Dunitz, London, 1989; pp. 301–306.
229. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide and attempted suicide. Arch Dermatol 2000; 136: 1231–1236.
230. Thiboutot DM. Acne and rosacea. new and emerging therapies. Dermatologic Clinics 2000; 18: 63–71.
231. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45: 515–519.
232. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470–481.
233. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626–631.
234. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399–408.
235. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996; 55: 273–275.
236. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478–485.
237. Kremer JM, Alarcon GS, Lightfoot RW Jr et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arth Rheum 1994; 37(3): 316–328.
238. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204–210.
239. Zonneveld IM, Bakker WK, Dijkstra PF et al. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996; 132: 184–187.
240. Chalmers RG, Boffa MJ. Methotroxate. J Dermatol Treatment 1997; 8: 36–43.
241. Dutz JP, Ho VC. Immunosuppressive agents in dermatology – an update. Dermatol Clin 1998; 16: 235–251.
242. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 51–53.
243. Ortiz, Shea B, Suarez-Almazor ME et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36–43.
244. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III collagen in routine screening for methotrexate – induced liver fibrosis: a 10 year follow-up. Br J Dermatol 2001; 144: 100–103.
245. Adu D, Cross J Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10: 203–208.
246. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54–56.
247. Powell AM, Al-Fares S, Albert S et al. Mycophenolate mofetil in immunobullous diseases: an evaluation of its usefulness. Br J Dermatol 2001; 145 (Suppl 59): 13–14.
248. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy of bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39: 497–498.
249. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 124: 1509–1511.
250. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporine to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405–407.
251. Grundmann-Kollmann M, Podda M, Ochsendorf F et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870–873.
252. Gaubitz M, Schorat A, Schotte H et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731–736.
253. Grundmann–Kollmann M, Podda M, Ochsendorf F et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870–873.
254. Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanisms, side effects and potential uses. J Am Acad Dermatol 1997; 37: 445–449.
255. Lipsky JL. Mycophenolate mofetil. Lancet 1996; 348: 1357–1359.
256. Nousari HC, Sragovich A, Kimyai-Asadi A et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265–268.
257. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. Q J Med 2000; 93:15–20.
258. Kolbach DN, Remme JJ, Bos WH et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133: 88–90.
259. Fivenson DP, Brenemen DL, Rosen GB et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753–758.
260. Handfield-Jones S, Jones S, Peachet R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1998; 118: 693–696.
261. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973; 29: 1180–1182.
262. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologica 1991; 34: 362–365.
263. McNeely W, Goa KL. 5-methoxypsoralen – a review of its effects in psoriasis and vitiligo. Drugs 1998: 56: 667–690.
264. Ibbotson SH, Farr PM. The time course of psoralen ultraviolet A (PUVA)erythema. J Invest Dermatol 1999; 113: 346–349.
265. Tanew A, Guggenbichler A, Honigsman H et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25: 682–684.
266. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994; 130: 246–255.
267. Stern RS, Laird N. The carcinogenicity risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 2759–2764.
268. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997; 336: 1041–1045.
269. Akaraphaanth R, Lim HW. HIV, UV and immunosuppression. Photodermatol, Photoimmunol, Photomed 1999; 15: 28–31.
270. Cooper EJ, Herd RM, Priestly GC, Hunter JAA. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000; 25: 111–114.
271. Drake LA, Dinehart SM, Farmer ER et al. Guidelines for care of vitiligo. J Am Acad Dermatol 1996; 35; 620–626.
272. Gupta AK, Anderson TF. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17: 703–734.
273. Honig B, Morison WL, Karp D. Photochemotherapy beyond psoriasis. J Am Acad Dermatol 1994; 31: 775–790.
274. Ortel B, Honigsmann H. Phototherapy and photochemotherapy. In Photodermatology. 1st edition. (Ed) Hawk JLM. Arnold, London, 1999.
275. Uetrecht J. Dapsone and sulphapyridine. Clinics in Dermatol 1989; 7: 111–120.
276. McFadden JP, Leonard JN, Powles AV et al. Sulphamethoxypuridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989; 121: 759–762.
277. Collier P, Wojnarowska F. Linear IgA disease and chronic bullous disease of childhood. Eur J Dermatol 1993; 3; 623-34.
278. Thornhill M, Pemberton M, Buchanan J et al. An open clinical trail of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid. Br J Dermatol 2000; 143: 117–126.
279. Fry L. Dermatitis herpetiformis. In Baillière’s Clinical Gastroenterology, Volume 9. (Ed) Howdle PD. Ballière Tindall, London, 1995 pp. 371–393.
280. Elder MJ, Leonard J, Dart JKG. Sulphapyridine – a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 549–552.
281. Bernstien JE, Lorincz MD. Sulfonamides and sulfones in dermatologic therapy. Int J Dermatol 1981; 20: 81–88.
282. Matilla MJ, Tiitineh H, Alhava E. Acetylation pattern of different sulfonamides in rapid and slow acetylators. Ann Med Exp Biol Fenn 1969; 47: 308.
283. Lindsay DG, Prlina L, Bischoff AJ et al. Cutaneous reactions due to sulphamethoxypyridazine. Arch Dermatol 1958; 78: 299–303.
284. Steinfort CL, Wiggins J, Sheffiels EA et al. Alveolitis associated with sulphamethoxypyridazine. Thorax 1989; 44: 310–311.
285. Sweetman S. (Ed) Martindale: The Complete Drug Reference. Pharmaceutical Press, London, 1999.
286. Somers GF. Pharmacological properties of thalidomide (-phthalimidoglutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960; 15: 111–116.
287. Tseng S, Pak G, Washenik K et al. Rediscovering thalidomide: a review of its mechanism of action, side-effects and potential uses. J Am Acad Dermatol 1996; 35: 969–979.
288. Radomsky CL, Levine N. Thalidomide. Dermatologic Clinics 2001; 19: 87–103.
289. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Dermato-Venereologica (Stockhl) 2000; 80: 24–25.
290. Powell RJ, Gardner-Medwin JMM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70: 910–904.
291. Harland CC, Stevenson GB, Marsden JR. Thalidomide induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995; 49: 1–6.
292. Harris AJ, Smith E, Sadoh DR et al. Thalidomide induced neuropathy: incidence and risk factors in 75 patients. Br J Dermatol 1998: 139 (Suppl 51): 24.
293. Ochonisky S, Verroust J, Bastujui-Garin S et al. Thalidomide neuropathy: incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66–69.
294. Bessmertny O, Pham T. Thalidomide use in pediatric patients. Ann Pharmacother 2002; 36: 521–525.
295. Chave TA, Finlay AY, Knight AG. Thalidomide usage in Wales: the need to follow guidelines. Br J Dermatol 2001; 144: 310–315.
296. Ordi-Ros J, Cortés F, Cucurull E et al. Thalidomide in the treatment of cutaneous lupus erythematosus refractory to conventional therapy. J Rheumatol 2000; 27: 1429–1433.
297. Radomsky CL, Levine N. Thalidomide. Dermatologic Clin 2001; 19: 87–103.
298. Ginsti RM, Iwaamoto, K, Hatch EE. Diethylstilboestrol – the effects of exposure in utero. Drugs and Therapeutics Bulletin 1991; 29: 135–139.2.
299. Rubin P. Drug treatment during pregnancy. BMJ 1998; 196: 135–139.
300. Reed BR. Dermatological drug use during pregnancy and lactation. Dermatologic Clinics 1997; 15: 197–206.
301. Reed BR. Dermatologic drugs, pregnancy and lactation. A conservative guide. Arch Dermatol 1997; 133: 894–898.
302. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arth Rheum 1995; 38: 1722–1732.
303. Collins, J (Ed). Preconception, pregnancy and prescribing. Drugs and Therapeutics Bulletin 1996; 34: 25–27.
304. Rawlins MD, Breckenridge AM, Wood SM et al. Focus on corticosteroids. Systemic corticosteroids in pregnancy and lactation. Current Problems in Pharmacovigilance 1998; 24: 5–10.
305. Maynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology 1998; 196: 135–139.
306. Perlman SE, Rudy SJ, Pinto C, Townsend-Akpan C. Caring for women with childbearing potentional taking teratogenic drugs. J Reprod Med. 2001; 46 (Suppl 2): 153–161.
307. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: 343–345.
308. Lacour M, Mehta-Nikhar B, Atherton DJ et al. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol 1996; 134: 1023–1029.
309. Zenk KE. Challenges in providing pharmaceutical care to paediatric patients. Am J Hosp Pharm 1994; 51: 688–694.
310. Sweetman S. (Ed) Martindale: The Complete Drug Reference. 32nd edition. Pharmaceutical Press, London, 1999.
311. American Hospital Formulary Service Drug Information. Board of American Society of Health System Pharmacists Inc, 1999.
312. Simons FE (on behalf of the ETAC Study Group). Prospective long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J All Clin Immunol 1999; 104: 433–440.
313. Aylett SE, Atherton DJ, Preece MA. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. Acta Derm Venereol (Stockh) 1992; Suppl 176: 123–125.
314. Sheenan MP, Atherton DJ, Norris P et al. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 1993; 129: 431–436.
315. Royal College of Paediatrics and Child Health. Medicines for Children. RCPCH, London, 1999.
316. European Agency for the Evaluation of Medicinal Products. Note for guidance on Clinical Investigation of Medicinal Products in Children. London, EAEMP, 1997.
317. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
318. Lin J-L, Shih I-H, Yu C-C. Haemodialysis related nodulocystic acne treated with isotretinoin. Nephron 1999; 81: 146–150.
319. Shah I, Whiting PH, Omar G et al. The effects of retinoids and terbinafine on human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 1993; 129: 395–398.
320. Arnoff GR, Bern JS, Brier MR et al. Drug prescribing in renal failure. In Dosing Guidelines for Adults. 4th edition. American College of Physicians, Philadelphia, Pennsylvania, 1999.
321. Bunn R, Ashley C. (Eds) The Renal Drug Handbook. UK Renal Pharmacy Group. Radcliffe Medical Press, Oxford, 1999.
322. Dollery CT. (Ed) Therapeutic Drugs. 2nd edition. Churchill Livingstone, Edinburgh, 1999.
323. Westphal JF, Vetter D, Brogard JM. Hepatic side effects of antibiotics. J Antimicrob Chemother 1994; 33: 387–401.
324. Javitt NB. Cholestatic liver disease and its management. Baillière’s Clin Gastroenterol 1989; 3: 423–430.
325. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711–716.
326. Bridges SL, Alarcon GS, Koopman WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatol 1989; 16: 1180–1183.
327. Kuijpers AL, van de Kerkhof PC. Risk–benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2002; 1: 27–39.
328. Fallon MB, Boyer JL. Hepatic toxicity of vitamin A and synthetic retinoids. J Gastroenterol and Hepatol 1990: 5: 334–342.
329. Stricker BH, Blok AP, Bronkhorst FB et al. Ketoconazole – associated hepatic injury. A clinicopathologic study of 55 cases. J Hepatol 1986; 3: 399–406.